-
Product Insights
NewAlpha Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Alpha Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Alpha thalassaemia (or α-thalassaemia) is a group of inherited blood disorders, characterised by a reduced production of the α-globin chains of the haemoglobin molecule, while the β-globin chains are normally produced. This means that there will be an accumulation of the β-(unpaired) globin chains, within the developing red cell. The production of the α-globin chains is regulated by four α-genes, two on...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Acquired Gene or Chromosome Alterations Pipeline Market Report Overview Acquired Gene or Chromosome Alterations are reagents employed for genetic testing to detect cancer-causing or related alterations. The Acquired Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Polycythemia Vera
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLN-124 in Polycythemia Vera Drug Details: SLN-124 is under development for the treatment of hereditary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mulnitorsen in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mulnitorsen in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mulnitorsen in Gastric Cancer Drug Details:Andes-1537 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-360 in Atherosclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-360 in Atherosclerosis Drug Details: SLN-360 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KHK-2455 in Adrenal Gland Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KHK-2455 in Adrenal Gland Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KHK-2455 in Adrenal Gland Cancer Drug Details:KHK-2455 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dexamethasone Sodium Phosphate in Duchenne Muscular Dystrophy Drug Details:Dexamethasone sodium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Primary (Inherited) Hemochromatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Primary (Inherited) Hemochromatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Primary (Inherited) HemochromatosisDrug Details: SLN-124 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Alpha Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Alpha Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Alpha ThalassaemiaDrug Details: SLN-124 is under development for the treatment of...